论文部分内容阅读
为提高完全缓解(CR)率,作者分三阶段进行了大剂量化疗和自体骨髓移植(ABMT)治疗骨髓瘤的研究.第一阶段,58例年龄小于63岁的患者接受了大剂量马法兰(HDM 140mg/m~2i.v.)治疗.初治者11/41例(27%)达CR,21例(51%)达部分缓解(PR),中数缓解期为19个月,2例过去对常规化疗有效者均达CR,对常规化疗无效的15例,66%的有效,其中2例达CR.但该组患者均在1年内复发,所有患者均有严重骨髓抑制,中度恶心,呕吐、粘膜炎,腹泻和可逆性脱发.10例在治疗2个月内死亡,主要死因为败血症和出血.第二阶段,在用HDM同时加用大剂量甲基强
To improve the rate of complete remission (CR), we conducted a high-dose chemotherapy and autologous bone marrow transplantation (ABMT) trial of myeloma in three phases: In the first phase, 58 patients younger than 63 years were treated with high-dose melphalan 21 (51%) achieved complete remission (PR), and the median remission was 19 months. Two of them were in the past CR was effective for conventional chemotherapy, 15 cases were ineffective for conventional chemotherapy, 66% effective, of which 2 cases of CR, but the group of patients relapsed within a year, all patients had severe myelosuppression, moderate nausea, Vomiting, mucositis, diarrhea and reversible alopecia.Of 10 patients died within 2 months of treatment, the main cause of death was sepsis and hemorrhage.The second phase, while using HDM plus large doses of methyl strong